PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 12

09/554,941 Application Number 05/22/2000 **Filing Date** Atkinson **First Named Inventor** 1638 **Group Art Unit** Kubelik, Anne **Examiner Name** S-30287A **Attorney Docket Number**

		ENCLOSURES	(check all that apply)
Fee Transmittal Form		Assignment Papers (for an Application)	After Allowance Communication to Group
Fee Attached	of	Drawing(s)	Appeal Communication to Board of Appeals and Interferences
Response to Notice Non-Compliant Amendment		Licensing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final		Petition	Proprietary Information
Affidavits/declaration(s)		Petition to Convert to a Provisional Application	Status Letter
Extension of Time Request		Power of Attorney, Revoca Change of Correspondenc Address	Other Enclosure(s) (please identify below):
		Terminal Disclaimer	Supplemental
Express Abandonment Reque	st 📗	Request for Refund	Amendment and
Information Disclosure Statem	ent 🔲	CD, Number of CD(s)	Return Postcard
Certified Copy of Priority Document(s)	Rem	arks	
Response to Missing Parts/ Incomplete Application			RECEIVED
Response to Missing Punder 37 CFR 1.52 or 1			NOV 2 0 2002
TECHLIFNIED 1600/0000			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT CENTER 1600/2900			
Firm Marcia R. Morton, Reg. No. 46,942 or Individual name Syngenta Biotechnology, Inc.			
Signature Marie R. Merten			
Signature ///	aren K.	Mente	
Date	11/12/1002		

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 11/12/2002 Melissa Hardy Typed or printed name 11/12/2002 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Application Serial No.: 09/554,941

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Washington, Dec 20231-0001

elissa Hardy

Type or print name

Mdintady Signature

11/2/02

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In Re Application of:

Atkinson et al.

Application Serial No.: 09/554,941

Filed: May 22, 2000

Title: DNA Encoding Proteinase Inhibitor

Fusion Proteins (new title)

Group Art Unit: 1638

Examiner: Kubelik, Anne

Atty Docket No.: S-30287A

RECEIVED

NOV 2 0 2002

TECH CENTER 1600/2900

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Commissioner for Patents Washington, D.C. 20231-0001

Honorable Commissioner:

In the Notice of Non-Compliant Amendment (37 C.F.R. § 1.121)("Notice"), dated October 17, 2002, the Office indicates that the Amendment filed on October 9, 2002, is considered non-compliant because it failed to meet the requirements of 37 C.F.R. § 1.121.

The Amendment filed October 9, 2002 presented four amendments to the specification, one of which did not include the text of the entire paragraph that was to be amended. In this Response, the amendment to the specification corrects this deficiency by including the text of that entire paragraph. Since both the Notice and subsequent oral instructions from the Office (from Sonya M. Williams, Patent Analyst), indicated that Applicants are not required to resubmit the entire Amendment,